News

Sanofi ramps up artemisinin plant
Enlarge image

BusinessItalyFranceBulgaria

Sanofi ramps up artemisinin plant

12.04.2013 - From its Italian manufacturing site at Garessio, Sanofi has launched large-scale production of semi-synthetic artemisinin, a potent anti-malarial drug.

The launch of the new facility on April 11 represents a further milestone in an anti-malarial drug partnership led by OneWorld Health, a non-profit drug development organisation, with funding from the Bill & Melinda Gates Foundation. Sanofi has invested €10m to build an industrial-scale plant that converts the biological precursor artemisinic acid into artemisinin in reaction steps that involve photochemistry. With its photochemical batch-flow-reactor technology in action, Sanofi envisions a production of 35 tonnes of semi-synthetic artemisinin in 2013, with the first batches available by this summer. It plans to increase capacity to 60 tonnes per year in 2014 and thereafter, which would meet at least a third of the annual global need for the drug. Sanofi hopes to get WHO approval for its product in the coming weeks.

From a technology perspective, the semi-synthetic artemisinin project is a combination of biotechnological and chemical know-how at the industrial scale. Artemisinin is a secondary metabolite extracted from the traditional Chinese medical herb Artemisia annua. However, the botanical supply is subject to climatic variables, leading to a fluctuation in antimalarial medicines and big price variations. Aiming for a stable and more reliable supply of the drug, Jay Keasling and his team at the University of California Berkeley and synthetic biology start-up Amyris genetically engineered yeast cells to produce the precursor artemisinic acid, which must then be converted into artemisinin by synthetic organic chemistry. Sanofi entered the project in 2008 as manufacturing partner with its Access to Medicines programme, and was involved in scaling-up fermentation of artemisinic acid and its conversion into artemisinin using photochemistry. At a facility run by Huverpharma in Bulgaria, an industrial-scale fermentation process was established that could produce up to 100 tonnes of artemisinic acid annually. It is considered as the first industrial-scale deployment of synthetic biology for drug production. Sanofi said it will provide its semi-synthetic artemisinin at a stable price using a non-profit, non-loss production model.

© eurobiotechnews.eu/pg

http://www.european-biotechnology-news.com/news/news/2013-02/sanofi-ramps-up-artemisinin-plant.html

LicencingDenmark

05.03.2015 Bavarian Nordic is outlicensing its Phase 3 prostate cancer immunotherapy Prostvac to pharma heavyweight Bristol Myers Squibb for a tidy €881m.

BusinessUK

03.03.2015 After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.47 CHF27.03%
  • BIOFRONTERA2.07 EUR4.02%
  • FORMYCON17.40 EUR3.02%

FLOP

  • STRATEC BIOMEDICAL43.50 EUR-3.59%
  • MEDIGENE4.55 EUR-1.94%
  • EVONIK30.88 EUR-1.66%

TOP

  • WILEX3.15 EUR47.9%
  • CYTOS0.47 CHF38.2%
  • EVOLVA1.69 CHF18.2%

FLOP

  • MOLOGEN5.27 EUR-13.7%
  • SANTHERA97.20 CHF-11.4%
  • 4SC0.77 EUR-9.4%

TOP

  • SANTHERA97.20 CHF2424.7%
  • WILEX3.15 EUR400.0%
  • FORMYCON17.40 EUR122.2%

FLOP

  • CYTOS0.47 CHF-83.4%
  • MOLOGEN5.27 EUR-57.2%
  • PAION2.09 EUR-55.5%

No liability assumed, Date: 04.03.2015